The Brazilian Journal of Implantology and Health Sciences cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

posted on June 19, 2024
The current issue of The Brazilian Journal of Implantology and Health Sciences (Volume 6, Issue 6 (2024), Page 1040-105) cites SOM3355 as a promising therapy for chorea in Huntington’s disease.
continue reading →

SOM Biotech appoints George G. Montgomery as Strategic Corporate Advisor

posted on May 28, 2024
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G. Montgomery as Strategic Corporate Advisor to the Board.
continue reading →

SOM Biotech announces the completion of recruitment in the Phase IIb study of the treatment of chorea in Huntington’s disease patients with SOM3355

posted on April 10, 2024
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.
continue reading →

SOM Biotech announces the election of Silvia Panigone as Executive Chair

posted on March 27, 2024
Barcelona, Spain, March 26th, 2024. SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary Artificial Intelligent (AI) platform, appoints Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.
continue reading →

SOM Biotech closes an internal round for €5.5 Million

posted on March 13, 2024
Barcelona, Spain. March 12, 2024. SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, announces the closure of an internal round for € 5.5 million to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355.…
continue reading →

SOM Biotech at the 10th Drug Discovery Innovation Programme

posted on November 29, 2019
SOM Biotech participated in the 10th Drug Discovery Innovation Programme that took place on November 28th -29th- in Barcelona, Spain. Luca Signorile – Computational Chemist of SOM Biotech –performed the presentation on the topic “Re-Discovering Drugs: Advantages, Perspectives, and the role of AI.” During his speech, he gave an insight into the computational side of…
continue reading →